The establishment of EVISA is funded by the EU through
the Fifth Framework Programme (G7RT- CT- 2002- 05112).
Supporters of EVISA includes:
Lobaplatin (D-19466; 1,2-diammino-methyl-cyclobutaneplatinum(II)-lactate) is a new anticancer agent and a representative of the third-generation platinum compounds. The metallodrug lobaplatin consists of a nearly 50%/50% mixture of two diastereoisomers: (a) the SSS configuration (LP-D1); and (b) the RRS configuration (LP-D2) (see left.) . The compound has shown antitumor activity in human lung, gastric, testicular, and ovarian cancer xenografts, with incomplete cross-resistance to cisplatin in vitro and in vivo.